{"title":"调整布地奈德/福莫特罗联合用药对哮喘症状缓解的影响。","authors":"Ryosuke Souma, Kumiya Sugiyama, Hiroyuki Masuda, Hajime Arifuku, Kentaro Nakano, Hiroyoshi Watanabe, Tomoshige Wakayama, Shingo Tokita, Masamitsu Tatewaki, Hideyuki Satoh, Kenya Koyama, Yumeko Hayashi, Fumiya Fukushima, Hirokuni Hirata, Masafumi Arima, Kazuhiro Kurasawa, Takeshi Fukuda, Yasutsugu Fukushima","doi":"10.1186/s40733-018-0043-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.</p><p><strong>Methods: </strong>Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.</p><p><strong>Results: </strong>Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, <i>p</i> < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, <i>p</i> < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = - 0.591X + 89.2 (r<sup>2</sup> = 0.299, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>As a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).</p>","PeriodicalId":8572,"journal":{"name":"Asthma research and practice","volume":"4 ","pages":"7"},"PeriodicalIF":0.0000,"publicationDate":"2018-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40733-018-0043-8","citationCount":"1","resultStr":"{\"title\":\"Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms.\",\"authors\":\"Ryosuke Souma, Kumiya Sugiyama, Hiroyuki Masuda, Hajime Arifuku, Kentaro Nakano, Hiroyoshi Watanabe, Tomoshige Wakayama, Shingo Tokita, Masamitsu Tatewaki, Hideyuki Satoh, Kenya Koyama, Yumeko Hayashi, Fumiya Fukushima, Hirokuni Hirata, Masafumi Arima, Kazuhiro Kurasawa, Takeshi Fukuda, Yasutsugu Fukushima\",\"doi\":\"10.1186/s40733-018-0043-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.</p><p><strong>Methods: </strong>Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.</p><p><strong>Results: </strong>Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, <i>p</i> < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, <i>p</i> < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = - 0.591X + 89.2 (r<sup>2</sup> = 0.299, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>As a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).</p>\",\"PeriodicalId\":8572,\"journal\":{\"name\":\"Asthma research and practice\",\"volume\":\"4 \",\"pages\":\"7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s40733-018-0043-8\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asthma research and practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40733-018-0043-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asthma research and practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40733-018-0043-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
背景:布地奈德+福莫特罗(BFC)联合应用具有根据哮喘症状在单一吸入器中调整剂量的优点。我们根据呼气峰流量(PEF)分析哮喘症状与患者剂量调整之间的关系。方法:28例使用BFC缓解症状的哮喘患者(男性12例,女性16例;根据症状的严重程度,可将吸入BFC的剂量增加到每天最多8次。患者每天早晚在哮喘日记中测量并记录PEF,同时记录他们的症状和服用的药物剂量。结果:28例患者中有16例因哮喘症状而增加剂量。以咳嗽为唯一症状时,哮喘症状恢复时间明显短于以呼吸困难或喘息为唯一症状时(1.4天vs. 5.3天或6.6天,p p 2 = 0.299, p)。结论:作为轻度哮喘患者有哮喘症状时增加BFC剂量的指导,当存在咳嗽或PEF降至88.9%时(即X = 0.5)应增加剂量。
Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms.
Background: The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.
Methods: Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.
Results: Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, p < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, p < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = - 0.591X + 89.2 (r2 = 0.299, p < 0.001).
Conclusion: As a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).
期刊介绍:
Asthma Research and Practice is the official publication of Interasma and publishes cutting edge basic, clinical and translational research in addition to hot topic reviews and debate articles relevant to asthma and related disorders (such as rhinitis, COPD overlapping syndrome, sinusitis). The journal has a specialized section which focusses on pediatric asthma research. Asthma Research and Practice aims to serve as an international platform for the dissemination of research of interest to pulmonologists, allergologists, primary care physicians and family doctors, ENTs and other health care providers interested in asthma, its mechanisms and comorbidities.